Ciphergen announces protein expression profiling patent issuance.
"We are delighted that the USPTO has acknowledged Differential Retentate Chromatography with a United States patent ," said William E. Rich, President and CEO of Ciphergen. "Clients of Ciphergen's Biomarker Discovery Centers and purchasers of our ProteinChip System are already using this powerful protein expression profiling method to discover and validate new protein biomarkers. This patent secures Ciphergen's exclusive right to the Differential Retentate Chromatography technology and, we believe, further enables our leadership in the field of clinical proteomics."
In the Differential Retentate Chromatography method of protein expression profiling, proteins from different biological samples are captured on a variety of chromatographic or affinity based biochip surfaces. The captured proteins are quantitatively detected directly "on-chip" by SELDI-time-of-flight mass spectrometry and compared in order to identify proteins that are present in different amounts in the samples. Proteins that are differentially present in two or more samples are candidate biomarkers for disease, toxicology or drug-responder status or may indicate pathway information.
"Many of Ciphergen's collaborators and customers, using this Differential Retentate Chromatography-based protein expression profiling method, have discovered multiple protein biomarkers in several different cancers, neurological disorders and other diseases," said Rich. "Further, several clinical studies have been recently reported at the American Association of Cancer Research meeting in New Orleans and published in the American Journal of Pathology showing that the use of multi-biomarkers in combination with advanced pattern recognition software can significantly increase the statistical confidence of a clinical diagnosis of disease. We believe that multi-biomarker strategies will yield significant advances in clinical diagnostics, including early detection of cancer. Ciphergen's future plans include marketing of clinical diagnostic systems and assays involving multi-biomarkers discovered using Differential Retentate Chromatography."
Ciphergen develops, manufactures and markets the ProteinChip System that enables protein discovery, characterization and assay development to provide researchers with a better understanding of biological functions at the protein level. The ProteinChip System is a novel, enabling tool in the emerging field of protein-based biology research, known as proteomics. Proteomics provides a direct approach to understanding the role of proteins in the biology of disease, monitoring of disease progression and the therapeutic effects of drugs. Ciphergen believes proteomics will be a major focus of biological research by enhancing the understanding of gene function and the molecular basis of disease.
|Printer friendly Cite/link Email Feedback|
|Comment:||Ciphergen announces protein expression profiling patent issuance.|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||May 1, 2001|
|Previous Article:||Vical obtains angiogenesis patent.|
|Next Article:||South Alabama Medical Science Foundation obtains United States patent.|